Article Sidebar
Published:
Nov 3, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparison of efficacy and safety profiles of rivaroxaban and aspirin versus clopidogrel and aspirin in the prevention of atherosclerotic events in Chinese dyslipidemic patients with coronary artery disease
Abstract
Purpose: To compare the efficacy and safety profiles of rivaroxaban (R) + aspirin (A) and clopidogrel (C) + aspirin (A) in the prevention of atherosclerotic events in Chinese dyslipidemic patients with coronary artery disease (CAD).
Methods: Coronary artery disease patients were given either R (10 mg daily) + A (100 mg daily) or C (75 mg daily) plus A (100 mg daily), with 105 subjects in each group. Each patient was followed up for 30 months. The following clinical outcomes (as aspects of primary endpoints) were assessed: percentge of patients with incidence of atherosclerotic events, and deaths due to any cause/cardiovascular causes. Hazard ratios and safety were also determined.
Results: A total of 210 enrolled patients completed the study. Compared to C + A group, patients treated with R + A had slightly lower incidence of atherosclerotic events (33.2 vs 32.6 %, p > 0.05) and lower death rate due to any cause/cardiovascular causes (3.1 vs 2 %, p > 0.05). Patients treated with R + A had significantly greater incidence of bleeding (p < 0.05).
Conclusion: The R + A treatment is more effective than C + A treatment in the prevention of atherosclerotic events, although this was not statistically significant different. The incidence of bleeding are significantly higher in R + A group than in C + A group.
